Clinical Trials /

Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

NCT01555892

Description:

Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease or severe chronic active Epstein Barr Virus (CAEBV) which has come back, is at risk of coming back, or has not gone away after treatment, including the best treatment we know for these diseases. Some patients with Lymphoma or T/NK-lymphoproliferative disease or CAEBV show signs of virus that is called Epstein Barr virus (EBV) that causes mononucleosis or glandular fever ("mono" or the "kissing disease") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with HD and NHL, suggesting that it may play a role in causing Lymphoma. The cancer cells (in lymphoma) and some immune system cells (in CAEBV) infected by EBV are able to hide from the body's immune system and escape destruction. We want to see if special white blood cells, called GRALE T cells, that have been trained to kill EBV infected cells can survive in the blood and affect the tumor. We have used this sort of therapy to treat a different type of cancer that occurs after bone marrow or solid organ transplant called post transplant lymphoma. In this type of cancer the tumor cells have 9 proteins made by EBV on their surface. We grew T cells in the lab that recognized all 9 proteins and were able to successfully prevent and treat post transplant lymphoma. However, in HD and NHL, T/NK-lymphoproliferative disease, and CAEBV, the tumor cells and B cells only express 4 EBV proteins. In a previous study, we made T cells that recognized all 9 proteins and gave them to patients with HD. Some patients had a partial response to this therapy but no patients had a complete response. We then did follow up studies where we made T cells that recognized the 2 EBV proteins seen in patients with lymphoma, T/NK-lymphoproliferative disease and CAEBV. Those proteins are called LMP-1 and LMP-2. The cells are called LMP-specific cytotoxic T-Lymphocytes (CTLs). We have treated over 45 people on those studies. About 63% of those patients who had disease at the time they got the cells had responses including some patients with complete responses. This study will expand on those results and we will try and make the T cells in the lab in a simpler faster way. We will also make T cells that will still see the LMP proteins but also 2 other EBV proteins called EBNA-1 and BARF. These cells are called GRALE T cells. These GRALE CTLs are an investigational product not approved by the FDA. The purpose of this study is to find the largest safe dose of LMP-specific cytotoxic GRALE T cells created using this new manufacturing technique. We will learn what the side effects are and to see whether this therapy might help patients with HD or NHL or EBV associated T/NK-lymphoproliferative disease or CAEBV.

Related Conditions:
  • Lymphoma
  • Mature T-Cell and NK-Cell Lymphoma/Leukemia
Recruiting Status:

Recruiting

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
  • Official Title: Administration of Rapidly Generated LMP, BARF1 And EBNA1 Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma

Clinical Trial IDs

  • ORG STUDY ID: H-29617-GRALE
  • SECONDARY ID: GRALE
  • SECONDARY ID: P50CA126752
  • NCT ID: NCT01555892

Conditions

  • Hodgkin's Disease
  • Non-Hodgkin's Lymphoma
  • Lymphoproliferative Disease
  • Lymphoma

Interventions

DrugSynonymsArms
LMP, BARF1 & EBNA1 specific CTLs: ALMP, BARF1 and EBNA1 specific CTLsLMP, BARF1 & EBNA1 specific CTLs: A
LMP, BARF1 & EBNA1 specific CTLs : BLMP, BARF1 & EBNA1 specific CTLs : B

Purpose

Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease or severe chronic active Epstein Barr Virus (CAEBV) which has come back, is at risk of coming back, or has not gone away after treatment, including the best treatment we know for these diseases. Some patients with Lymphoma or T/NK-lymphoproliferative disease or CAEBV show signs of virus that is called Epstein Barr virus (EBV) that causes mononucleosis or glandular fever ("mono" or the "kissing disease") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with HD and NHL, suggesting that it may play a role in causing Lymphoma. The cancer cells (in lymphoma) and some immune system cells (in CAEBV) infected by EBV are able to hide from the body's immune system and escape destruction. We want to see if special white blood cells, called GRALE T cells, that have been trained to kill EBV infected cells can survive in the blood and affect the tumor. We have used this sort of therapy to treat a different type of cancer that occurs after bone marrow or solid organ transplant called post transplant lymphoma. In this type of cancer the tumor cells have 9 proteins made by EBV on their surface. We grew T cells in the lab that recognized all 9 proteins and were able to successfully prevent and treat post transplant lymphoma. However, in HD and NHL, T/NK-lymphoproliferative disease, and CAEBV, the tumor cells and B cells only express 4 EBV proteins. In a previous study, we made T cells that recognized all 9 proteins and gave them to patients with HD. Some patients had a partial response to this therapy but no patients had a complete response. We then did follow up studies where we made T cells that recognized the 2 EBV proteins seen in patients with lymphoma, T/NK-lymphoproliferative disease and CAEBV. Those proteins are called LMP-1 and LMP-2. The cells are called LMP-specific cytotoxic T-Lymphocytes (CTLs). We have treated over 45 people on those studies. About 63% of those patients who had disease at the time they got the cells had responses including some patients with complete responses. This study will expand on those results and we will try and make the T cells in the lab in a simpler faster way. We will also make T cells that will still see the LMP proteins but also 2 other EBV proteins called EBNA-1 and BARF. These cells are called GRALE T cells. These GRALE CTLs are an investigational product not approved by the FDA. The purpose of this study is to find the largest safe dose of LMP-specific cytotoxic GRALE T cells created using this new manufacturing technique. We will learn what the side effects are and to see whether this therapy might help patients with HD or NHL or EBV associated T/NK-lymphoproliferative disease or CAEBV.

Detailed Description

      Subjects (or their syngeneic donor) will give blood for investigators to make
      LMP/BARF1/EBNA-1 (GRALE) CTLs in the lab. These cells will be grown and frozen for the
      subject.

      Patients will be started on the lowest dose (1 of 3 different levels) of GRALE T cells. Once
      that dose schedule proves safe, the next group of patients will be started at a higher dose.
      This process will continue until all 3 dose levels are studied. If the side effects are too
      severe, the dose will be lowered or the GRALE T cell injections will be stopped.

      The GRALE T cells will then be thawed and injected into the subject over 2-10 minutes.
      Initially, two doses of GRALE T cells will be given 2 weeks apart.

      If after the 2nd infusion there is a reduction in the size of the lymphoma on CT or MRI scan
      as assessed by a radiologist, the subject can receive additional doses of the GRALE T cells
      if they wish (up to 6 times). Follow up testing will be collected just like after the 1st
      infusion.

      All of the treatments will be given by the Center for Cell and Gene Therapy at Texas
      Children's Hospital or Houston Methodist Hospital.

      We will follow the subjects after the injections. They will either be seen in the clinic or
      the subject will be contacted by a research nurse yearly for 5 years.

      If they receive additional doses of the GRALE T cells as described above, they will be
      followed until 5 years after the last dose of GRALE T-cells.
    

Trial Arms

NameTypeDescriptionInterventions
LMP, BARF1 & EBNA1 specific CTLs: AExperimentalGroup A: Patients in second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiple relapsed patients in remission who are at a high risk of relapse)** or any patient with primary disease or in first or subsequent remission if immunosuppressive chemotherapy is contraindicated. Each group will have the dose escalation done separately. Two patients will be entered at the starting dose level. Each patient will receive 2 injections, 14 days apart, according to the dosing schedules. If there are no dose limiting toxicities, the escalation will continue at the pre-specified dose levels. ** Patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant.
  • LMP, BARF1 & EBNA1 specific CTLs: A
LMP, BARF1 & EBNA1 specific CTLs : BExperimentalGroup B: Patients in remission or with minimal residual disease (MRD) status after autologous or syngeneic SCT. Each group will have the dose escalation done separately. Two patients will be entered at the starting dose level. Each patient will receive 2 injections, 14 days apart, according to the dosing schedules. If there are no dose limiting toxicities, the escalation will continue at the pre-specified dose levels.
  • LMP, BARF1 & EBNA1 specific CTLs : B

Eligibility Criteria

        Inclusion Criteria at time of Procurement

          1. Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's
             Lymphoma, (regardless of the histological subtype) or EBV
             (associated)-T/NK-lymphoproliferative disease or Severe Chronic Active EBV (CAEBV) who
             may subsequently be eligible for the treatment component

          2. EBV positive tumor (can be pending at this time)

          3. Weighs at least 12kg

          4. Informed consent explained to, understood by and signed by patient/guardian.
             Patient/guardian given copy of informed consent.

        Inclusion Criteria at time of Infusion

          1. Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's
             Lymphoma (regardless of histologic subtype), or EBV
             (associated)-T/NK-lymphoproliferative disease or Severe Chronic Active EBV (CAEBV) and

             In second or subsequent relapse (or first relapse or with active disease if
             immunosuppressive chemotherapy contraindicated or multiply relapsed patients in
             remission who have a high risk of relapse) OR any patient with primary disease or in
             first remission if immunosuppressive chemotherapy is contraindicated, e.g. patients
             who develop Hodgkin disease after solid organ transplantation or if the Lymphoma is a
             second malignancy e.g. a Richter's transformation of CLL. (Group A)

             OR

             In remission or with minimal residual disease status after autologous or syngeneic
             SCT. (Group B)

          2. EBV positive tumor

          3. Patients with life expectancy greater than or equal 6 weeks.

          4. Patients with bilirubin less than or equal to 3x upper limit of normal, AST less than
             or equal 5x upper limit of normal, and Hgb greater than or equal to 7.0 (may be a
             transfused value).

          5. Patients with a creatinine less than or equal to 2x upper limit of normal for age

          6. Pulse oximetry of > 90% on room air

          7. Patients should have been off other investigational therapy for 4 weeks prior to entry
             in this study.

          8. Patients with a Karnofsky/Lansky score of greater than or equal to 50

          9. Sexually active patients must be willing to utilize one of the more effective birth
             control methods during the study and for 6 months after the study is concluded. The
             male partner should use a condom.

         10. Informed consent explained to, understood and signed by patient/guardian.
             Patient/guardian given copy of informed consent.

               -  CAEBV is defined as patients with high EBV viral load in plasma or PBMC (> 4000
                  genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV

                    -  Patients with relapsed or refractory lymphoma that are eligible for a stem
                       cell transplant will not be treated on this study as an alternative to
                       transplant.

        Exclusion Criteria at Time of Procurement

        1. Active infection with HIV, HTLV, HBV, HCV (can be pending at this time)

        Exclusion Criteria at Time of Infusion

          1. Pregnant or lactating

          2. Severe intercurrent infection.

          3. Current use of systemic corticosteroids > 0.5 mg/kg/day
      
Maximum Eligible Age:N/A
Minimum Eligible Age:N/A
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Assessment of toxicity of escalating doses of LMP, BARF1 and EBNA1 CTLs
Time Frame:8 weeks
Safety Issue:
Description:To determine the safety of escalating doses of 2 intravenous injections of autologous or syngeneic rapid LMP, BARF1 and EBNA1 specific cytotoxic T-lymphocytes (CTL) in patients with EBV-associated Hodgkin's Disease or non-Hodgkin's lymphoma or T/NK-lymphoproliferative disease and CAEBV.

Secondary Outcome Measures

Measure:Determine survival and immune function of LMP/BARF1/EBNA1-specific cytotoxic T-lymphocyte lines
Time Frame:1 year
Safety Issue:
Description:To determine the survival and the immune function of LMP/BARF1/EBNA1-specific cytotoxic T-lymphocyte lines
Measure:Assess anti-viral and anti-tumor effects of LMP/BARF1/EBNA1-specific CTL
Time Frame:1 year
Safety Issue:
Description:To assess the anti-viral and anti-tumor effects of LMP/BARF1/EBNA1--specific CTL
Measure:Obtain preliminary information on safety and response to extended dosage regimen
Time Frame:1 year
Safety Issue:
Description:To obtain preliminary information on the safety and response to an extended dosage regimen.

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Baylor College of Medicine

Trial Keywords

  • EBV
  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • Lymphoma Relapse
  • Autologous or Syngeneic Stem Cell Transplant
  • T/NK-lymphoproliferative disease
  • LMP
  • BARF1
  • EBNA1

Last Updated